JCP Capital

Founded in 2000, JCP Capital is a venture capital firm based in Hong Kong. The firm seeks to make investments in the DeepTech and HealthTech space including sectors and themes like Semiconductor, AIoT, smart manufacturing, Artificial Intelligence & Digitization, New material, Carbon neutral, bio-pharmacy, vitro diagnostic and treatment tools, and medical equipment.

Xuelong Hu Ph.D

Managing Partner

5 past transactions

Emergen

Series B in 2021
Zhejiang Zhichang Group is a cluster of robots and intelligent manufacturing enterprises founded by Dr. Gan Middle School, the first batch of national “Thousand Talents Program” experts. It has two independent core technologies: distributed intelligent robot controller and HCPS intelligent intellectual network. Three single-arm robots and smart factory eco-networks are three high-end intelligent manufacturing business areas. Committed to the development of robotic products with independent intellectual property rights, breaking the monopoly of foreign brands in the field of key components of robots, and truly realizing the national dream of "intellectual creation".

MingMed

Series A in 2021
Researcher and developer of pharmaceutical drugs. The company develops ophthalmic drugs, small molecule immune drugs, and cell therapies based on gene editing, providing innovative products to ophthalmology, medical beauty and pet medicine.

Vbao

Series B in 2021
Vbao is a provider of asset management and trading solutions specifically tailored for insurance companies. The company develops various platforms focused on enhancing business productivity and operational efficiency. Its core offerings include an insurance premium management platform, investment and trading software, and an insurance account management system. These products are designed to deliver integrated, reliable, and efficient transaction and account management solutions, catering to the unique needs of the insurance sector. By focusing on these specialized tools, Vbao aims to streamline processes and improve performance for its clients in the insurance industry.

MingMed

Series A in 2021
Researcher and developer of pharmaceutical drugs. The company develops ophthalmic drugs, small molecule immune drugs, and cell therapies based on gene editing, providing innovative products to ophthalmology, medical beauty and pet medicine.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.